INS and type 2 diabetes mellitus: As such, the reduced adiposity and improved insulin action coupled with the ability to preserve functional β-cell mass observed under the inhibition of NPY/Y1 signaling in vivo highlights a potential therapy for targeting peripheral Y1 receptor pathways, which may ultimately provide greater therapeutic benefits in controlling glucose levels in T2D.